General MedicationsSUBCUTANEOUSStandard
SOGROYA
SOMAPACITAN-BECO
Standard Dose
10MG/1.5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SOGROYA is listed in Drugs@FDA under application 761156 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient SOMAPACITAN-BECO Form and strength SOLUTION;SUBCUTANEOUS - 10MG/1.5ML Sponsor NOVO NORDISK INC Submission history Latest submission status date: 2026-02-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview SOGROYA is listed in Drugs@FDA under application 761156 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient SOMAPACITAN-BECO Form and strength SOLUTION;SUBCUTANEOUS - 10MG/1.5ML Sponsor NOVO NORDISK INC Submission history Latest submission status date: 2026-02-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.